Orion Oyj

Director's Dealing • Feb 28, 2025

Disclosure 455553

Orion - Managers' transactions

Orion Corporation: Managers' transactions - Outi Vaarala

ORION CORPORATION

MANAGERS’ TRANSACTIONS

28 FEBRUARY 2025 at 17.45 EET

Orion Corporation: Managers’ transactions – Outi Vaarala

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Orion Oyj - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Outi Vaarala

Position: Other senior manager

Issuer: Orion Oyj

LEI: 74370029VAHCXDR7B745

Notification type: INITIAL NOTIFICATION

Reference number: 98180/7/4

____________________________________________

Transaction date: 2025-02-26

Venue: NASDAQ HELSINKI LTD (XHEL)

Instrument type: SHARE

ISIN: FI0009014377

Nature of transaction: DISPOSAL

Transaction details

(1): Volume: 2000 Unit price: 54.54 EUR

Aggregated transactions (1):

Volume: 2000 Volume weighted average price: 54.54 EUR

Orion Corporation

Liisa Hurme President and CEO		Olli Huotari Executive Vice President, Corporate Functions

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland

http://www.orionpharma.com

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2024 amounted to EUR 1,542 million and the company had about 3,700 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.